Background

Partial epigenetic reprogramming via transient OSKM expression reverses epigenetic age (GrimAge, DunedinPACE) without dedifferentiation. Independently, statins (HMGCR inhibitors) extend healthspan in epidemiological studies beyond cardiovascular benefit, with unexplained reductions in senescence markers and inflammatory disease incidence (including RA and SLE flares).

Hypothesis

The mevalonate pathway intermediate geranylgeranyl-pyrophosphate (GGPP) maintains EZH2 membrane sequestration via RhoA geranylgeranylation, depleting nuclear EZH2 and reducing H3K27me3 at pluripotency-associated loci. This creates an epigenetic barrier to endogenous partial reprogramming (stochastic low-level OSKM-like transcription factor activity). Statins, by blocking GGPP synthesis, release EZH2 from membrane-tethered RhoA, increasing nuclear EZH2 availability and enabling H3K27me3 remodeling that lowers the activation energy for partial epigenetic rejuvenation.

Testable Predictions

1. Statin-treated aged mice will show increased nuclear EZH2/cytoplasmic EZH2 ratio in hepatocytes and fibroblasts compared to vehicle, independent of LDL changes.
2. GGPP supplementation will abolish statin-mediated epigenetic age reversal (measured by Horvath multi-tissue clock) despite maintained cholesterol reduction via dietary means.
3. In human fibroblasts, simvastatin pre-treatment (48h) will increase OSKM-driven partial reprogramming efficiency (iPSC colony count at day 7, terminated before full reprogramming) by >40% vs vehicle.
4. RhoA constitutively active mutant (RhoA-Q63L, geranylgeranylation-independent membrane targeting) will block statin-mediated nuclear EZH2 redistribution and reprogramming facilitation.
5. Rheumatoid arthritis patients on chronic statin therapy will show decelerated DunedinPACE vs matched non-statin RA patients in existing longitudinal cohorts (e.g., CORRONA registry), adjustable for cardiovascular confounders.

Significance

This mechanism would unify the unexplained extra-cardiovascular benefits of statins under a geroscience framework, identify GGPP as a druggable epigenetic aging accelerator, and suggest that statin-EZH2 axis modulation could enhance therapeutic partial reprogramming protocols. For autoimmune diseases, it provides a molecular rationale for statin adjunct therapy targeting biological (not just chronological) aging.